AP
IMNM icon

Antipodes Partners’s Immunome IMNM Stock Holding History

Antipodes Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$171K Sell
7,818
-1,016
-12% -$22.6K ﹤0.01% 87
2025
Q4 		$190K Sell
8,834
-2,058
-19% -$36.1K ﹤0.01% 87
2025
Q3 		$128K Buy
10,892
+631
+6% +$6.28K ﹤0.01% 82
2025
Q2 		$95.4K Sell
10,261
-3,903
-28% -$32K ﹤0.01% 76
2025
Q1 		$95.3K Buy
+14,164
New +$136K ﹤0.01% 73

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Antipodes Partners's IMNM Position: Q1 2026 in Review

Antipodes Partners reduced its Immunome (IMNM) stake by 12% in Q1 2026, selling an estimated $22.6K and leaving 7,818 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #87.

Antipodes Partners first reported a position in IMNM in Q1 2025 and has held it in 5 quarters since. The position peaked at $190K in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Antipodes Partners held 7,818 shares of Immunome worth $171K as of Q1 2026.
  • Antipodes Partners sold 1,016 Immunome shares in Q1 2026, an estimated $22.6K.
  • Immunome made up ﹤0.01% of Antipodes Partners's portfolio in Q1 2026, its #87 holding.
  • Antipodes Partners first reported a position in Immunome in Q1 2025 and has held it in 5 quarters since.
  • Antipodes Partners's Immunome position peaked at $190K in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.